Argenx
NASDAQ:ARGXBiotechNetherlands · Est. 2008
7
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
28
Indications↗
Distinct diseases across all programs
106
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
7 drugs in development
Approved1
Phase 33
Phase 25
Phase 14
Preclinical2
By Therapeutic Area
top 4
Neurology
533%
Immunology
213%
Cardiovascular
213%
Hematology
17%
R&D Momentum
73/100
Pipeline Velocity
42/100
Trial Completion Rate
85/100
Pipeline Concentration
26/100
Pipeline Freshness
81/100
Strategic Signals
- ↗Active in Immunology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 5, 2026
Recruiting
ISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Nov 5, 2026
Active, not recruiting
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Nov 5, 2026
Active, not recruiting
A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients With Multifocal Motor Neuropathy
Nov 5, 2026
Active, not recruiting
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis
Nov 4, 2026
Recruiting
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Nov 4, 2026
Recruiting
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
Nov 4, 2026
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
Nov 4, 2026
Recruiting
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
Nov 4, 2026
Enrolling by invitation
A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Oct 30, 2026
Active, not recruiting
Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis
Oct 28, 2026
Recruiting
A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy
Details
Company Info
Therapeutic Focus
OtherNeurologyHematologyCardiovascularImmunology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(2 drugs)
1
—
—
2
—
Cardiovascular(2 drugs)
Hematology(1 drug)
—
—
1
1
—
Hematology(1 drug)
Immunology(2 drugs)
—
—
1
2
1
Immunology(2 drugs)
Neurology(5 drugs)
1
2
5
2
1
Neurology(5 drugs)
Unknown / Other(5 drugs)
—
2
2
2
1
Unknown / Other(5 drugs)
Regulatory
Regulatory Timeline
20213 events
FDADec 17
Vyvgart — VYVGART
Application BLA761195
FDADec 17
VYVGART — VYVGART
Application BLA761195 (BLA)
FDADec 17
Vyvgart — VYVGART
Application BLA761195 (BLA)
20234 events
FDADec 12
Vyvgart — VYVGART
Application BLA761195
FDADec 12
Vyvgart — VYVGART HYTRULO
Application BLA761304
FDAJun 20
VYVGART HYTRULO — VYVGART HYTRULO
Application BLA761304 (BLA)
FDAJun 20
Vyvgart — VYVGART HYTRULO
Application BLA761304
20245 events
FDAAug 8
Vyvgart — VYVGART
Application BLA761195
FDAAug 8
Vyvgart — VYVGART HYTRULO
Application BLA761304
FDAJul 24
Vyvgart — VYVGART
Application BLA761195
FDAJun 21
Vyvgart — VYVGART HYTRULO
Application BLA761304
FDAJun 21
Vyvgart — VYVGART HYTRULO
Application BLA761304
20253 events
FDAOct 17
Vyvgart — VYVGART HYTRULO
Application BLA761304
FDAOct 17
Vyvgart — VYVGART
Application BLA761195
FDAApr 10
Vyvgart — VYVGART HYTRULO
Application BLA761304
20263 events
FDAMay 8
Vyvgart — VYVGART
Application BLA761195
FDAMay 8
Vyvgart — VYVGART HYTRULO
Application BLA761304
FDAFeb 26
Vyvgart — VYVGART HYTRULO
Application BLA761304
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)